Biotech Archives - Page 765 of 795

1 minute read

Pfizer/BioNTech Start Phase 2 Trial For COVID-19 Vaccine Against Omicron Subvariant

July 27, 1:48 PM

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) initiated a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response…

BNTX

1 minute read

Medicenna’s Lead Cancer Program Shows Preliminary Anti-Cancer Activity In Solid Tumor Study

By Vandana Singh

July 27, 1:42 PM

Medicenna Therapeutics Corp (NASDAQ:MDNA) announced new clinical data from the Phase 1/2 ABILITY study of MDNA11. The data provide preliminary evidence…

MDNA

1 minute read

FDA
News

CDC Set To Make Monkeypox A Nationally Notifiable Condition; New Designation Will Take Effect Aug. 1

By Benzinga Newsdesk

July 27, 1:32 PM

-Politico Report

AEMD

1 minute read

FDA
News

GSK Announces U.S. FDA Approval of Benlysta (Belimumab) For Pediatric Patients With Active Lupus Nephritis

By Benzinga Newsdesk

July 27, 1:20 PM

GSK plc (NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving

GSK

1 minute read

Cidara Pursues FDA Approval For Bloodstream Infections Candidate

By Ragothaman Srinivasan

July 27, 10:35 AM

Cidara Therapeutics, Inc. (NASDAQ: CDTX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead asset Rrezafungin for the treatment of candidemia and invasive candidiasis.

CDTX

1 minute read

FDA
News

Bavarian Nordic Is Now Allowed To Deliver Jynneos/Imvanex Smallpox And Monkeypox Vaccine Manufactured At Its Own Site To U.S. And EU Market

By Benzinga Newsdesk

July 27, 10:23 AM

-Reuters

AEMD

1 minute read

Medicenna Announces New Clinical Data Providing Preliminary Evidence Of MDNA11’s Single Agent Anti-Cancer Activity In The Phase 1/2 ABILITY Study

By Benzinga Newsdesk

July 27, 8:16 AM

-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled in the ABILITY Study’s low and mid-stage dose escalation cohorts --

MDNA

2 minute read

Mustang Bio Announces First Patient Successfully Treated By Ex Vivo Lentiviral Gene Therapy To Treat RAG1 Severe Combined Immunodeficiency

By Benzinga Newsdesk

July 27, 8:14 AM

Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for

MBIO

3 minute read

Bluejay Diagnostics Highlights PResentatin At AACC 2022

By Bill Haddad

July 27, 7:43 AM

Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical

BJDX

1 minute read

Soligenix Receives Agreement From FDA On Initial Pediatric Study Plan For HyBryte For The Treatment Of Cutaneous T-Cell Lymphoma

By Bill Haddad

July 27, 7:35 AM

Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced

SNGX